Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T23:37:17.764Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical psychopharmacology: some current problems

Published online by Cambridge University Press:  09 July 2009

M. H. Lader
M. H. Lader
Affiliation:
Department of Psychiatry, Institute of Psychiatry, University of London, and the Department of Pharmacology, University College London
Get access Rights & Permissions [Opens in a new window]

Summary

Some current problems in clinical psychopharmacology are examined and pharmacological approaches towards their elucidation outlined and discussed. Particular topics reviewed include the concepts of potency and maximum effect, the balance between wanted and unwanted effects, and the problems of heterogeneity and variability as they apply to patients and their responses to psychotropic drugs. Types of methods for the assessment of drug effects are listed and the growing importance and relevance of pharmacokinetic studies stressed. A more general and intensive use of the pharmacological approach is urged in order to acquire much-needed basic data on psychotropic drug action in man.

Type
Research Article
Information
Psychological Medicine , Volume 1 , Issue 2 , February 1971 , pp. 150 - 158
Copyright
Copyright © Cambridge University Press 1971

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Alexanderson, B., Evans, D. A. P., and Sjöqvist, F. (1969). Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. British Medical Journal, 4, 764–768.CrossRefGoogle ScholarPubMed
Beecher, H. K. (1955). The powerful placebo. Journal of the American Medical Association, 159, 1602–1606.CrossRefGoogle ScholarPubMed
Blackwell, B., and Marley, E. (1966). Interactions of cheese and of its constituents with monoamine oxidase inhibitors. British Journal of Pharmacology and Chemotherapy, 26, 120–141.CrossRefGoogle ScholarPubMed
Conney, A. H. (1967). Pharmacological implications of microsomal enzyme induction. Pharmacological Reviews, 19, 317–366.Google ScholarPubMed
Curry, S. H. (1968a). Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromalography with an electron capture detector. Analytical Chemistry, 40, 1251–1255.CrossRefGoogle Scholar
Curry, S. H. (1968b). The determination and possible significance of plasma levels of chlorpromazine in psychiatric patients. Agressologie, 9, 115–121.Google ScholarPubMed
Curry, S. H., Davis, J. M., Janowsky, D. S., and Marshall, J. H. L. (1970). Factors affecting chlorpromazine plasma levels in psychiatric patients. Archives of General Psychiatry, 22, 209–215.CrossRefGoogle ScholarPubMed
Fingl, E., and Woodbury, D. M. (1965). General principles. In The Pharmacological Basis of Therapeutics, pp. 136. Edited by Goodman, L. S., and Gilman, A.. Macmillan: New York.Google Scholar
Freyhan, F. A. (1959). Therapeutic implications of differential effects of new phenothiazine compounds. American Journal of Psychiatry, 115, 577–585.CrossRefGoogle ScholarPubMed
Gaddum, J. H. (1954). Clinical pharmacology. Proceedings of the Royal Society of Medicine. 47, 195–204.CrossRefGoogle ScholarPubMed
Hill, A. B. (Editor) (1960). Controlled Clinical Trials. Blackwell: Oxford.Google Scholar
Hollister, L. E., Curry, S. H., Derr, J. E., and Kanter, S. L. (1970). Studies of delayed-action medication. V. Plasma levels and urinary excretion of four different dosage forms of chlorpromazine. Clinical Pharmacology and Therapeutics, 11, 49–59.CrossRefGoogle ScholarPubMed
Lader, M. H., Sakalis, G., and Tansella, M. (1970). Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia, 18, 118–123.CrossRefGoogle Scholar
Lasagna, L. (1955). The controlled clinical trial: theory and practice.Journal of Chronic Diseases, 1, 353–367.CrossRefGoogle ScholarPubMed
Levy, G., and Nelson, E. (1961). Pharmaceutical formulation and therapeutic efficacy. Journal of the American Medical Association, 177, 689–691.CrossRefGoogle ScholarPubMed
Mattke, D. J. (1968). A pilot investigation in neuroleptic therapy. Diseases of the Nervous System, 29, 515–524.Google ScholarPubMed
Medical Research Council (1965). Clinical trial of the treatment of depressive illness. British Medical Journal, 1, 881–886.CrossRefGoogle Scholar
Mehta, D. J. (1963). ‘Potency’ and ‘efficacy’ of drugs. Journal of New Drugs, 3, 12–14.CrossRefGoogle ScholarPubMed
National Institute of Mental Health (1964). Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry, 10, 246–261.CrossRefGoogle Scholar
Parke, D. V. (1968). The Biochemistry of Foreign Compounds. Pergamon: Oxford.Google Scholar
Prescott, L. F. (1969). Pharmacokinetic drug interactions. Lancet, 2, 1239–1243.CrossRefGoogle ScholarPubMed
Rickels, K. (1962). The controlled clinical trial in psycho-pharmacologic research. In Psychosomatic Medicine. The First Hahnemann Symposium, pp. 421–426. Edited by Nodine, J. H., and Moyer, J. H.. Kimpton: London.Google Scholar
Rickels, K. (Editor) (1968). Non-specific Factors in Drug Therapy. Thomas: Springfield, Illinois.Google Scholar
Shepherd, M., Lader, M., and Rodnight, R. (1968). Clinical Psychopharmacology. English Universities Press: London.Google Scholar
Sjöqvist, F., Hammer, W., Borgå, O., and Azarnoff, D. L. (1969). Pharmacological significance of the plasma level of monomethylated tricyclic antidepressants. In The Present Status of Psychotropic Drugs, pp. 128–136. Edited by Cerletti, A., and Bové, F. J.. Excerpta Medica: Amsterdam.Google Scholar
Weatherall, M. (1966). The meaning and importance of drug potency in medicine. Clinical Pharmacology and Therapeutics, 7, 577–582.CrossRefGoogle ScholarPubMed